ArticleActa pharmacologica Sinica2015
Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer.
Article in Acta pharmacologica Sinica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- IL-37/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells.Oncoimmunology · 2026Review
- Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review).International journal of molecular medicine · 2026Review
- Interleukin-37 in Cancer Angiogenesis: Mechanisms, Therapeutic Potential, and Future Perspectives.Cancer reports (Hoboken, N.J.) · 2026Review
- Potential pro-tumour cytokine in oral squamous cellular carcinoma: IL37.Journal of cellular and molecular medicine · 2024Article
- The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response.Oncoimmunology · 2024Article
- Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process.Frontiers in immunology · 2023Review
- The role of IL-35 and IL-37 in breast cancer - potential therapeutic targets for precision medicine.Frontiers in oncology · 2022Review
- IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.Theranostics · 2020Article
- Inhibition of human cervical cancer cell invasion by IL-37 involving runt related transcription factor 2 suppression.Annals of translational medicine · 2019Article
- IL-37: An anti-inflammatory cytokine with antitumor functions.Cancer reports (Hoboken, N.J.) · 2019Review
- IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma.Cancer management and research · 2019Article
- IL-37 promotes cell apoptosis in cervical cancer involving Bim upregulation.OncoTargets and therapy · 2019Article
- Prognostic significance of nomograms integrating IL-37 expression, neutrophil level, and MMR status in patients with colorectal cancer.Cancer medicine · 2018Article
- The Role, Involvement and Function(s) of Interleukin-35 and Interleukin-37 in Disease Pathogenesis.International journal of molecular sciences · 2018Review
- The novel role of IL-37 in prostate cancer: evidence as a promising radiosensitizer.Medical oncology (Northwood, London, England) · 2017Article
- Interleukin-37 mediates the antitumor activity in colon cancer through β-catenin suppression.Oncotarget · 2017Article
- Circulating tumor cells promote the metastatic colonization of disseminated carcinoma cells by inducing systemic inflammation.Oncotarget · 2017Article
- The role of IL-37 in cancer.Medical oncology (Northwood, London, England) · 2016Review
- IL-37b gene transfer enhances the therapeutic efficacy of mesenchumal stromal cells in DSS-induced colitis mice.Acta pharmacologica Sinica · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIL-37b has shown anti-cancer activities in addition to its anti-inflammatory properties. In this study, we investigated the effects of IL-37b on breast carcinoma growth in mice and to determine the involvement of T cell activation in the effects.
methodsIL-37b gene was transferred into mouse breast carcinoma cell line 4T1 (4T1-IL37b cells), the expression of secretory IL-37b by the cells was detected, and the effects of IL-37b expression on the cell proliferation in vitro was evaluated. After injection of 4T1 cells or 4T1-IL37b cells into immunocompetent BALB/c mice, immunodeficient BALB/c nude mice and NOD-SCID mice, the tumor growth and survival rate were measured. The proliferation of T cells in vitro was also detected.
resultsIL-37b was detected in the supernatants of 4T1-IL37b cells with a concentration of 12.02 ± 0.875 ng/mL. IL-37b expression did not affect 4T1 cell proliferation in vitro. BALB/c mice inoculated with 4T1-IL37b cells showed significant retardation of tumor growth. BALB/c mice inoculated with both 4T1 cells and mitomycin C-treated 4T1-IL37b cells also showed significant retardation of tumor growth. But the anti-cancer activity of IL-37b was abrogated in BALB/c nude mice and NOD-SCID mice inoculated with 4T1-IL37b cells. Recombinant IL-37b slightly promoted CD4(+) T cell proliferation without affecting CD8(+) T cell proliferation.
conclusionIL-37b exerts anti-4T1 breast carcinoma effects in vivo by modulating the tumor microenvironment and influencing T cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.